Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (UM1 Clinical Trial Required)

This notice of funding opportunity (NOFO) encourages applications to establish a Rapid-Acting Psychotropic Interventional Drugs - Clinical Trials Network (RAPIDs-CTN). The overarching purpose is to generate actionable, real-world evidence to guide the safe and effective implementation of RAPIDs in routine clinical practice, answering urgent questions about how these treatments can be delivered sustainably outside tightly controlled experimental settings. This NOFO utilizes a milestone-driven UM1 Cooperative Agreement mechanism structured into two operational stages: Stage 1 (Years 1–2) for network establishment and pilot studies, and Stage 2 (Years 3–5) focuses for full-scale execution of proposed pragmatic trials. This program is intended only for large-scale, coordinated network projects that could not be achieved using other, more standard grant mechanisms. Eligibility: Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

Estimated total programme funding: USD 12000000

Expected number of awards: 3

CFDA number(s): 93.24R

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.